Diabetes drug ‘increases bladder cancer risk by 63%’, study suggests
Pioglitazone, a drug used to treat people with diabetes, could increase bladder cancer risk, suggests new research in the BMJ.
Huffington Post (Source: Society for Endocrinology)
Source: Society for Endocrinology - March 31, 2016 Category: Endocrinology Source Type: news
More Evidence Diabetes Drug Actos Raises Bladder Cancer Risk a Bit
But odds are small, and experts want it to remain on market, although newer drugs are available (Source: U.S. News - Health)
Source: U.S. News - Health - March 31, 2016 Category: Consumer Health News Source Type: news
More Evidence Diabetes Drug Actos Raises Bladder Cancer Risk a Bit
Title: More Evidence Diabetes Drug Actos Raises Bladder Cancer Risk a BitCategory: Health NewsCreated: 3/30/2016 12:00:00 AMLast Editorial Review: 3/31/2016 12:00:00 AM (Source: MedicineNet Diabetes General)
Source: MedicineNet Diabetes General - March 31, 2016 Category: Endocrinology Source Type: news
Pioglitazone Bladder Cancer Link Seen Again (CME/CE)
(MedPage Today) -- But absolute risk remains low overall, finds large British study (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - March 31, 2016 Category: Endocrinology Source Type: news
More Evidence Diabetes Drug Actos Raises Bladder Cancer Risk a Bit
But odds are small, and experts want it to remain on market, although newer drugs are available (Source: Cancercompass News: Other Cancer)
Source: Cancercompass News: Other Cancer - March 31, 2016 Category: Cancer & Oncology Source Type: news
Large cohort study confirms link between pioglitazone, bladder cancer
Pioglitazone was linked to a 63% increase in bladder cancer risk, compared with other noninsulin antidiabetic drugs in a large population-based cohort study.
Furthermore, incidence rose the longer... (Source: Clinical Endocrinology News)
Source: Clinical Endocrinology News - March 30, 2016 Category: Endocrinology Source Type: news
Large cohort study confirms link between pioglitazone, bladder cancer
Pioglitazone was linked to a 63% increase in bladder cancer risk, compared with other noninsulin antidiabetic drugs in a large population-based cohort study.
Furthermore, incidence rose the longer... (Source: Family Practice News)
Source: Family Practice News - March 30, 2016 Category: Primary Care Source Type: news
More Evidence Diabetes Drug Actos Raises Bladder Cancer Risk a Bit
But odds are small, and experts want it to remain on market, although newer drugs are available (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - March 30, 2016 Category: Cancer & Oncology Authors: webmaster at doctorslounge.com Tags: Oncology, Pharmacy, Diabetes, News, Source Type: news
Pioglitazone Again Tied to Increased Risk for Bladder Cancer (FREE)
By Amy Orciari Herman
Edited by Susan Sadoughi, MD
The diabetes drug pioglitazone is associated with increased risk for bladder cancer, according to a large population-based study in The BMJ. Prior research has gone back and forth … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - March 30, 2016 Category: Primary Care Source Type: news
More Evidence Diabetes Drug Actos Raises Bladder Cancer Risk a Bit
WEDNESDAY, March 30, 2016 -- More evidence linking the diabetes drug Actos to an increased risk of bladder cancer has surfaced in a new study that also finds the risk rises with increased use.
Actos (pioglitazone) appears to increase risk of... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 30, 2016 Category: Journals (General) Source Type: news
Study confirms link between diabetes drug and increased risk of bladder cancer
(BMJ) The diabetes drug pioglitazone is associated with an increased risk of bladder cancer, finds a study published by The BMJ today. The findings suggest that the risk increases with increasing duration of use and dose. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 30, 2016 Category: Cancer & Oncology Source Type: news
Diabetes Drugs Have Positive Effect in MSDiabetes Drugs Have Positive Effect in MS
Metformin and pioglitazone help regulate immune and inflammatory responses in obese patients with multiple sclerosis who also have metabolic syndrome, a new study suggests. Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - March 22, 2016 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
Diabetes Drug May Stop Stroke, Help Lipids
Pioglitazone may prevent repeated cardiovascular events in some patients. Combined with omega-3 fatty acids, the drug also can improve lipid metabolism. (Source: ConsultantLive)
Source: ConsultantLive - March 1, 2016 Category: Internal Medicine Authors: Mark L. Fuerst Tags: Cardiovascular Diseases News Diabetes Source Type: news
New front opens in battle against stroke
Medical scientists have vetted a potentially powerful new tool for helping prevent stroke and heart attack. In a study, researchers show that pioglitazone, a member of the insulin-sensitizing class of medications called thiazolidinediones, reduced the risk of stroke or heart attack by almost a quarter in patients who had previously suffered a stroke or mini-stroke. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - February 25, 2016 Category: Science Source Type: news
Novel Target in Crosshairs for Obesity and T2DM (CME/CE)
(MedPage Today) -- Natriuretic peptide dysregulation in diabetes responded to pioglitazone (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - February 22, 2016 Category: Endocrinology Source Type: news
